[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the State Street",
    "url": "https://finnhub.io/api/news?id=28f3e1b83005c18a9b7332804b490c0641821e2e6dbd771c88726d24a992b43e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770411005,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 138379656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the State Street",
      "url": "https://finnhub.io/api/news?id=28f3e1b83005c18a9b7332804b490c0641821e2e6dbd771c88726d24a992b43e"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement?",
    "summary": "The company's market-leading HIV franchise has fueled top-line growth.",
    "url": "https://finnhub.io/api/news?id=619b6f4cecad6207d4713ee9b3b4847aa9400dd84c1c0da52d6f0a70c50807e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770396240,
      "headline": "Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement?",
      "id": 138378296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The company's market-leading HIV franchise has fueled top-line growth.",
      "url": "https://finnhub.io/api/news?id=619b6f4cecad6207d4713ee9b3b4847aa9400dd84c1c0da52d6f0a70c50807e5"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma",
    "summary": "SANTA MONICA, Calif., February 06, 2026--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell thera",
    "url": "https://finnhub.io/api/news?id=2e3fe3199ba958516a504ebe39960b4b9dcca2bb1787f27b3091aba49cbfb495",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770384600,
      "headline": "FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma",
      "id": 138374457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., February 06, 2026--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell thera",
      "url": "https://finnhub.io/api/news?id=2e3fe3199ba958516a504ebe39960b4b9dcca2bb1787f27b3091aba49cbfb495"
    }
  }
]